M R Weir1, M Moser. 1. Division of Nephrology, University of Maryland School of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Abstract
BACKGROUND: Hypertension is a major risk factor for cardiovascular disease, particularly in combination with other risk factors such as obesity, smoking, diabetes, and dyslipidemia. Effective management of hypertension, even a modest reduction in blood pressure, results in reduced mortality and morbidity from cerebrovascular and cardiovascular disease. METHODS: Data from clinical trials were examined to assess the effect of low-dose diuretics or beta-blockers on lipoprotein profile. RESULTS: Results of numerous clinical trials demonstrate that low doses of thiazides or cardioselective beta-blockers alone or in combination result in minimal changes in lipid profile. CONCLUSIONS: Low doses of thiazide diuretics or beta-blockers are a safe and effective approach to the management of uncomplicated essential hypertension and have the advantage of an association with an evidence-based reduction in morbidity and mortality in long-term clinical trials. There is little or no evidence that the minimal changes in serum lipid profile associated with use of these drugs have resulted in a negation of the beneficial effects of these agents on blood pressure.
BACKGROUND:Hypertension is a major risk factor for cardiovascular disease, particularly in combination with other risk factors such as obesity, smoking, diabetes, and dyslipidemia. Effective management of hypertension, even a modest reduction in blood pressure, results in reduced mortality and morbidity from cerebrovascular and cardiovascular disease. METHODS: Data from clinical trials were examined to assess the effect of low-dose diuretics or beta-blockers on lipoprotein profile. RESULTS: Results of numerous clinical trials demonstrate that low doses of thiazides or cardioselective beta-blockers alone or in combination result in minimal changes in lipid profile. CONCLUSIONS: Low doses of thiazide diuretics or beta-blockers are a safe and effective approach to the management of uncomplicated essential hypertension and have the advantage of an association with an evidence-based reduction in morbidity and mortality in long-term clinical trials. There is little or no evidence that the minimal changes in serum lipid profile associated with use of these drugs have resulted in a negation of the beneficial effects of these agents on blood pressure.
Authors: Catharine R Gale; G David Batty; Sally-Ann Cooper; Ian J Deary; Geoff Der; Bruce S McEwen; Jonathan Cavanagh Journal: Psychosom Med Date: 2015-06 Impact factor: 4.312
Authors: Cornel Pater; Deepak Bhatnagar; Jean-Pascal Berrou; Joachim Luszick; Katrin Beckmann Journal: Curr Control Trials Cardiovasc Med Date: 2004-10-01